Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Eur J Clin Invest. 2017 Feb 11;47(3):231–240. doi: 10.1111/eci.12729

Table 2.

Primary and secondary endpoints stratified according LVEF

Ischemic heart dis-
ease, LVEF <30%
n=37
Ischemic heart
disease, LVEF 30–
39% n=54
Ischemic heart dis-
ease, LVEF 40–49%
n=29
Control
subjects
n=30
All-cause mortality n=16 (43%) n=18 (33%) n=11 (38%) n=1 (3%)
Cardiac death (CD) n=14 (38%) n=13 (24%) n=7 (24%) 0
Arrhythmic death (AD) / Re-
susciated cardiac arrest
(RCA)
n=11 (30%) n=20 (37%) n=9 (31%) 0